NO329497B1 - Anvendelse av polystyrensulfonat for fremstilling av medikament for behandling av antibiotikumassosiert eller C. difficile-assosiert diare. - Google Patents
Anvendelse av polystyrensulfonat for fremstilling av medikament for behandling av antibiotikumassosiert eller C. difficile-assosiert diare. Download PDFInfo
- Publication number
- NO329497B1 NO329497B1 NO20015524A NO20015524A NO329497B1 NO 329497 B1 NO329497 B1 NO 329497B1 NO 20015524 A NO20015524 A NO 20015524A NO 20015524 A NO20015524 A NO 20015524A NO 329497 B1 NO329497 B1 NO 329497B1
- Authority
- NO
- Norway
- Prior art keywords
- toxin
- polymer
- mmol
- solution
- added
- Prior art date
Links
- 229920001467 poly(styrenesulfonates) Polymers 0.000 title claims description 66
- 229960002796 polystyrene sulfonate Drugs 0.000 title claims description 56
- 239000011970 polystyrene sulfonate Substances 0.000 title claims description 56
- 238000011282 treatment Methods 0.000 title claims description 29
- 206010012735 Diarrhoea Diseases 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title claims description 15
- 241000193163 Clostridioides difficile Species 0.000 title description 30
- 230000003115 biocidal effect Effects 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 title description 3
- 229940079593 drug Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 abstract description 100
- 239000003053 toxin Substances 0.000 abstract description 63
- 231100000765 toxin Toxicity 0.000 abstract description 62
- 241001465754 Metazoa Species 0.000 abstract description 47
- 238000000034 method Methods 0.000 abstract description 12
- 239000002095 exotoxin Substances 0.000 abstract description 8
- 231100000776 exotoxin Toxicity 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 3
- 125000006850 spacer group Chemical group 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 68
- 108700012359 toxins Proteins 0.000 description 61
- 239000000499 gel Substances 0.000 description 48
- 239000000203 mixture Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 29
- 101710182532 Toxin a Proteins 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 24
- 229960000282 metronidazole Drugs 0.000 description 24
- -1 poly(styrene sulphonate) Polymers 0.000 description 24
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 101710182223 Toxin B Proteins 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 16
- 239000000594 mannitol Substances 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 206010009887 colitis Diseases 0.000 description 15
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 14
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 14
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 14
- 230000005587 bubbling Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 241000699800 Cricetinae Species 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920002223 polystyrene Polymers 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 108010059993 Vancomycin Proteins 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 8
- 229960003165 vancomycin Drugs 0.000 description 8
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000011553 hamster model Methods 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- YRVUCYWJQFRCOB-UHFFFAOYSA-N n-butylprop-2-enamide Chemical compound CCCCNC(=O)C=C YRVUCYWJQFRCOB-UHFFFAOYSA-N 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 231100000757 Microbial toxin Toxicity 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000001147 anti-toxic effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000147 enterotoxin Substances 0.000 description 4
- 231100000655 enterotoxin Toxicity 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- AWDYCSUWSUENQK-UHFFFAOYSA-N n-decylprop-2-enamide Chemical compound CCCCCCCCCCNC(=O)C=C AWDYCSUWSUENQK-UHFFFAOYSA-N 0.000 description 4
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001464 poly(sodium 4-styrenesulfonate) Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- OUEBKBVJKXETSH-UHFFFAOYSA-N octane-1-sulfinamide Chemical compound CCCCCCCCS(N)=O OUEBKBVJKXETSH-UHFFFAOYSA-N 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920002959 polymer blend Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical group ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000024033 toxin binding Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004873 levomenthol Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- MAGFQRLKWCCTQJ-UHFFFAOYSA-M 4-ethenylbenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(C=C)C=C1 MAGFQRLKWCCTQJ-UHFFFAOYSA-M 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QWOKKHXWFDAJCZ-UHFFFAOYSA-N octane-1-sulfonamide Chemical compound CCCCCCCCS(N)(=O)=O QWOKKHXWFDAJCZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012852 risk material Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13397599P | 1999-05-13 | 1999-05-13 | |
| US09/541,268 US6270755B1 (en) | 1999-05-13 | 2000-04-03 | Anionic polymers as toxin binders |
| PCT/US2000/012943 WO2000069428A2 (en) | 1999-05-13 | 2000-05-11 | Anionic polymers as toxin binders and antibacterial agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20015524D0 NO20015524D0 (no) | 2001-11-12 |
| NO20015524L NO20015524L (no) | 2002-01-11 |
| NO329497B1 true NO329497B1 (no) | 2010-11-01 |
Family
ID=26831853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015524A NO329497B1 (no) | 1999-05-13 | 2001-11-12 | Anvendelse av polystyrensulfonat for fremstilling av medikament for behandling av antibiotikumassosiert eller C. difficile-assosiert diare. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6270755B1 (zh) |
| EP (1) | EP1189622B1 (zh) |
| JP (1) | JP2002544226A (zh) |
| KR (1) | KR100742433B1 (zh) |
| CN (1) | CN100435806C (zh) |
| AT (1) | ATE367818T1 (zh) |
| AU (1) | AU768592B2 (zh) |
| BR (1) | BR0011520A (zh) |
| CA (1) | CA2374108A1 (zh) |
| DE (1) | DE60035689T2 (zh) |
| DK (1) | DK1189622T3 (zh) |
| ES (1) | ES2288855T3 (zh) |
| HK (1) | HK1044490A1 (zh) |
| HU (1) | HUP0201114A3 (zh) |
| IL (2) | IL146211A0 (zh) |
| MY (1) | MY132695A (zh) |
| NO (1) | NO329497B1 (zh) |
| NZ (1) | NZ515226A (zh) |
| PL (1) | PL197157B1 (zh) |
| PT (1) | PT1189622E (zh) |
| RU (1) | RU2246938C2 (zh) |
| TW (1) | TW592704B (zh) |
| WO (1) | WO2000069428A2 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290946B1 (en) * | 1999-05-13 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders and antibacterial agents |
| US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
| US6805857B2 (en) * | 2000-03-06 | 2004-10-19 | Kumarpal A. Shah | Method of modulating factor D, factor H and CD4 cell immune response with a polystyrene sulfonate, alginate, and saline infusion solution |
| CA2314494A1 (en) * | 2000-05-02 | 2001-11-02 | Geltex Pharmaceuticals, Inc. | Anionic polymers as species specific antibacterial agents |
| US6537538B2 (en) * | 2000-12-18 | 2003-03-25 | Rush-Presbyterian-St. Luke's Medical Center | Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate |
| KR20050030208A (ko) * | 2002-07-22 | 2005-03-29 | 젠자임 코포레이션 | 폴리(칼륨 및 나트륨 스티렌 설포네이트), 이의 제조방법및 용도 |
| DE60330161D1 (de) * | 2002-08-29 | 2009-12-31 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
| US7682631B2 (en) * | 2003-10-01 | 2010-03-23 | Clemson University | Adhesin-specific nanoparticles and process for using same |
| US20050106267A1 (en) | 2003-10-20 | 2005-05-19 | Framework Therapeutics, Llc | Zeolite molecular sieves for the removal of toxins |
| WO2006044577A1 (en) * | 2004-10-13 | 2006-04-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| US20060078534A1 (en) * | 2004-10-13 | 2006-04-13 | Dominique Charmot | Toxin binding compositions |
| WO2007024973A1 (en) * | 2005-08-22 | 2007-03-01 | Quick-Med Technologies, Inc. | Disinfectant with quaternary ammonium polymers and copolymers |
| AU2006310096A1 (en) * | 2005-11-02 | 2007-05-10 | Oplon B.V. | Compositions and methods for cell killing |
| TW200829286A (en) * | 2006-09-06 | 2008-07-16 | Genzyme Corp | Polystyrene sulfonate polymer tablets, their preparation and use |
| US8809444B2 (en) * | 2009-12-23 | 2014-08-19 | Momentive Performance Materials Inc. | Network copolymer crosslinked emulsions and demulsifying compositions comprising the same |
| JP5820112B2 (ja) * | 2010-12-15 | 2015-11-24 | 積水化学工業株式会社 | インフルエンザウイルス感染阻止剤、インフルエンザウイルス感染阻止塗料及びインフルエンザウイルス感染阻止製品 |
| CN102160870B (zh) * | 2011-03-18 | 2013-04-24 | 南京欧睿医药科技有限公司 | 聚（4-苯乙烯磺酸-共聚-马来酸）钠盐的用途及其药物组合物 |
| CA2845091A1 (en) * | 2011-09-08 | 2013-03-14 | Safe Bt, Inc. | Use of modified hollow fiber materials for removing exotoxins produced by escherichia coli from liquids, preferably from blood and plasma as well as their use for treating concomitant diseases |
| RU2482883C1 (ru) * | 2012-03-12 | 2013-05-27 | Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук | Способ получения полимерно-композиционных волокнистых материалов с антимикробной активностью |
| KR102674230B1 (ko) * | 2014-12-23 | 2024-06-11 | 알데릭스, 인코포레이티드 | 고칼륨혈증의 치료를 위한 조성물 및 방법 |
| KR101720053B1 (ko) | 2015-04-30 | 2017-03-27 | 이현국 | 고주파 열처리 장치 및 고주파 열처리 방법 |
| DE102022132913A1 (de) | 2022-12-12 | 2024-06-13 | Forschungszentrum Jülich GmbH | Block-Copolymer, Verfahren zur Herstellung eines Block-Copolymers, Membran und Verwendung einer Membran |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224941A (en) | 1963-01-21 | 1965-12-21 | Lilly Co Eli | Resin compositions and method for controlling diarrhea |
| US3466365A (en) | 1967-07-24 | 1969-09-09 | White Lab Inc | Antiviral compositions and method of use |
| NL7401542A (zh) * | 1973-02-09 | 1974-08-13 | ||
| IE44690B1 (en) | 1976-02-04 | 1982-02-24 | Rohm & Haas | Pharmaceutical compositions containing polyvinylbenzenosulfonic acids |
| US4395392A (en) | 1980-06-24 | 1983-07-26 | Adria Laboratories Inc. | Method for treating kidney stones |
| US4362711A (en) | 1980-07-11 | 1982-12-07 | Evreka Inc. | Blood cholesterol level reducing agent and method |
| US5171738A (en) | 1982-10-04 | 1992-12-15 | Toray Industries, Inc. | Method of treating malignant tumors |
| US5435821A (en) | 1985-12-12 | 1995-07-25 | Exxon Research & Engineering Co. | Controlled release vegetation enhancement agents coated with sulfonated polymers, method of production and prcesses of use |
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| JPS6422551A (en) * | 1987-07-16 | 1989-01-25 | Dainippon Ink & Chemicals | Composite film for lid |
| JPH0219319A (ja) | 1988-05-26 | 1990-01-23 | Duphar Internatl Res Bv | ラクツロースシロップから単離したフラクション及びこれを有効成分とする抗内毒素作用を有する医薬組成物 |
| JPH02176351A (ja) | 1988-12-27 | 1990-07-09 | Matsushita Electric Ind Co Ltd | 給湯器 |
| US5149523A (en) | 1989-06-20 | 1992-09-22 | Aktiebolaget Hassle | Polystyrenesulfonate-drug complex and solid dosage forms thereof |
| US5093130A (en) | 1989-09-26 | 1992-03-03 | Plant Genetics | Powder coated hydrogel capsules |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| FR2669535A1 (fr) * | 1990-11-26 | 1992-05-29 | Medgenix Group Sa | Utilisation a titre de medicament de macromolecules polysulfonees. |
| ATE162081T1 (de) * | 1991-09-17 | 1998-01-15 | Alcon Lab Inc | Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen |
| US5424063A (en) | 1992-01-09 | 1995-06-13 | The Dow Chemical Company | Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process |
| US5277820A (en) | 1992-02-06 | 1994-01-11 | Hemocleanse, Inc. | Device and method for extracorporeal blood treatment |
| US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5380522A (en) * | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
| US5643562A (en) | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5614559A (en) | 1993-11-23 | 1997-03-25 | Procept Inc. | Compound for inhibiting HIV infectivity |
| US5484773A (en) | 1994-02-14 | 1996-01-16 | Alberta Research Council | Treatment of antibiotic associated diarrhea |
| US5756810A (en) | 1994-03-11 | 1998-05-26 | Pharmacopeia, Inc. | Process of preparing 3-nitro benzoate compounds in lower alkanol |
| NZ291659A (en) | 1994-09-06 | 2001-04-27 | Galagen Inc | Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile |
| CA2208745C (en) | 1994-12-26 | 2001-02-13 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for endotoxin, tumor necrosis factor-.alpha. or interleukins, process for adsorbing and removing the same, and adsorber for the same |
| US5610023A (en) | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| DE19549420A1 (de) | 1995-04-27 | 1997-09-18 | Braun Melsungen Ag | Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma |
| AUPN327695A0 (en) * | 1995-05-30 | 1995-06-22 | Chemeq Pty. Limited | Chemotherapeutic compositions |
| US5700458A (en) * | 1996-09-20 | 1997-12-23 | Geltex Pharmaceuticals Inc. | Acid-functionalized saccharides as polyvalent anti-infectives |
| US5800803A (en) | 1997-02-10 | 1998-09-01 | Colgate-Palmolive Company | Oral composition exhibiting enhanced uptake by dental tissue of noncationic antibacterial agents |
| US6060235A (en) | 1997-09-19 | 2000-05-09 | Geltex Pharmaceuticals, Inc. | Antiviral polymers comprising acid functional groups and hydrophobic groups |
| US6007803A (en) * | 1997-09-19 | 1999-12-28 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin binding agents |
| WO1999020285A1 (fr) | 1997-10-16 | 1999-04-29 | Sanwa Kagaku Kenkyusho Co., Ltd. | Preparations de gels contenant un polystyrenesulfonate |
| US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
-
2000
- 2000-04-03 US US09/541,268 patent/US6270755B1/en not_active Expired - Lifetime
- 2000-05-09 MY MYPI20001992A patent/MY132695A/en unknown
- 2000-05-10 TW TW089108898A patent/TW592704B/zh not_active IP Right Cessation
- 2000-05-11 AU AU48409/00A patent/AU768592B2/en not_active Ceased
- 2000-05-11 ES ES00930620T patent/ES2288855T3/es not_active Expired - Lifetime
- 2000-05-11 KR KR1020017014459A patent/KR100742433B1/ko not_active IP Right Cessation
- 2000-05-11 PT PT00930620T patent/PT1189622E/pt unknown
- 2000-05-11 AT AT00930620T patent/ATE367818T1/de not_active IP Right Cessation
- 2000-05-11 IL IL14621100A patent/IL146211A0/xx active IP Right Grant
- 2000-05-11 NZ NZ515226A patent/NZ515226A/en not_active IP Right Cessation
- 2000-05-11 RU RU2001133465/15A patent/RU2246938C2/ru not_active IP Right Cessation
- 2000-05-11 JP JP2000617887A patent/JP2002544226A/ja active Pending
- 2000-05-11 DE DE60035689T patent/DE60035689T2/de not_active Expired - Lifetime
- 2000-05-11 WO PCT/US2000/012943 patent/WO2000069428A2/en active IP Right Grant
- 2000-05-11 CN CNB008075360A patent/CN100435806C/zh not_active Expired - Fee Related
- 2000-05-11 BR BR0011520-7A patent/BR0011520A/pt not_active Application Discontinuation
- 2000-05-11 EP EP00930620A patent/EP1189622B1/en not_active Expired - Lifetime
- 2000-05-11 DK DK00930620T patent/DK1189622T3/da active
- 2000-05-11 HU HU0201114A patent/HUP0201114A3/hu unknown
- 2000-05-11 PL PL352411A patent/PL197157B1/pl not_active IP Right Cessation
- 2000-05-11 CA CA002374108A patent/CA2374108A1/en not_active Abandoned
-
2001
- 2001-06-11 US US09/878,843 patent/US6419914B2/en not_active Expired - Fee Related
- 2001-10-28 IL IL146211A patent/IL146211A/en not_active IP Right Cessation
- 2001-11-12 NO NO20015524A patent/NO329497B1/no not_active IP Right Cessation
-
2002
- 2002-08-28 HK HK02106350.9A patent/HK1044490A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329497B1 (no) | Anvendelse av polystyrensulfonat for fremstilling av medikament for behandling av antibiotikumassosiert eller C. difficile-assosiert diare. | |
| US7678369B2 (en) | Anionic polymers as toxin binders and antibacterial agents | |
| JPH10505358A (ja) | クロストリジウム・ディフィシル関連疾患の治療処置 | |
| Laohachai et al. | The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea | |
| Duan et al. | Inhibition of CFTR-mediated intestinal chloride secretion as potential therapy for bile acid diarrhea | |
| Maina et al. | Staphylococcal enterotoxin A has potent superantigenic and emetic activities but not diarrheagenic activity | |
| RU2193407C2 (ru) | Фармацевтические препараты для лечения гастритов, рефлюкс-эзофагитов, дуоденитов, диспепсии и язвы | |
| Philipson | Antibiotic treatment in Lyme borreliosis | |
| EP1800687A2 (en) | Anionic polymers as toxin binders and antibacterial agents | |
| MXPA01011387A (es) | Polimeros anionicos como ligantes de toxinas y agentes antibacterianos | |
| ZA200109290B (en) | Anionic polymers as toxin binders and antibacterial agents. | |
| Koníčková et al. | Effect of carbenicillin, gentamicin, and their combination on experimental Pseudomonas aeruginosa urinary tract infection | |
| ES2551726T3 (es) | Ion bismuto para su uso en la prevención y/o tratamiento del síndrome hemolítico urémico | |
| RU2180849C2 (ru) | Способ подавления гемолитической активности патогенных штаммов кишечной палочки | |
| Hung et al. | Role of histamine and acid back-diffusion in modulation of gastric microvascular permeability and hemorrhagic ulcers in Salmonella typhimurium-infected rats | |
| Gart | Role of colonic epithelial cells in susceptibility and severity of Citrobacter rodentium infection in mice | |
| Wenisch et al. | Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea | |
| ADLER | Common things are common depending upon where you live | |
| Hardy | Aetiology of Hirschsprung's disease associated enterocolitis | |
| Dragstedt | Studies in intestinal obstruction | |
| Dudeja | Clostridium difficile Toxins A and B Decrease Intestinal SLC26A3 Protein Expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |